Standout Papers

Pegaptanib for Neovascular Age-Related Macular Degeneration 2003 2026 2010 2018 1.8k
  1. Pegaptanib for Neovascular Age-Related Macular Degeneration (2004)
    Evangelos S. Gragoudas, Anthony P. Adamis et al. New England Journal of Medicine
  2. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease (2006)
    Eugene W. M. Ng, David T. Shima et al. Nature Reviews Drug Discovery
  3. A central role for inflammation in the pathogenesis of diabetic retinopathy (2004)
    Antonia M. Joussen, Vassiliki Poulaki et al. The FASEB Journal
  4. Ten years of anti-vascular endothelial growth factor therapy (2016)
    Napoleone Ferrara, Anthony P. Adamis Nature Reviews Drug Discovery
  5. Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies (2003)
    Jayakrishna Ambati, Balamurali K. Ambati et al. Survey of Ophthalmology
  6. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials (2013)
    David M. Brown, Quan Dong Nguyen et al. Ophthalmology
  7. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition (1999)
    Kazuaki Miyamoto, Sven–Erik Bursell et al. Proceedings of the National Academy of Sciences
  8. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury (2007)
    Kazuaki Nishijima, Yin‐Shan Ng et al. American Journal Of Pathology
  9. Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman Primate (1996)
    Anthony P. Adamis Archives of Ophthalmology
  10. A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema (2005)
    Emmett T. Cunningham, Anthony P. Adamis et al. Ophthalmology
  11. Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study (2011)
    David M. Brown, Peter A. Campochiaro et al. Ophthalmology
  12. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration (2019)
    Peter A. Campochiaro, Dennis M. Marcus et al. Ophthalmology

Immediate Impact

26 by Nobel laureates 15 from Science/Nature 123 standout
Sub-graph 1 of 16

Citing Papers

Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout
Top-down design of protein architectures with reinforcement learning
2023 StandoutScienceNobel
1 intermediate paper

Works of Anthony P. Adamis being referenced

Pegaptanib for Neovascular Age-Related Macular Degeneration
2004 Standout
Suppression of Diabetic Retinopathy with Angiopoietin-1
2002
and 1 more

Author Peers

Author Last Decade Papers Cites
Anthony P. Adamis 13052 8868 8393 114 20.8k
Joan W. Miller 11048 6458 6710 366 16.1k
Reinier O. Schlingemann 7193 5248 4159 183 12.4k
David A. Antonetti 6526 3406 5487 121 12.4k
Gerard A. Lutty 6193 4205 4306 166 10.6k
Gregory S. Hageman 8902 5014 5128 144 11.9k
Karl G. Csaky 5250 3292 3205 144 8.9k
David S. Boyer 14402 10900 2975 165 16.2k
Jayakrishna Ambati 4059 2098 2985 99 6.9k
Rajendra S. Apte 3300 2150 2853 155 8.2k
Bruce A. Keyt 2479 2057 5076 75 9.8k

All Works

Loading papers...

Rankless by CCL
2026